Global ADCs Market to grow at a CAGR of 41.58% during the period 2016 - 2020; Finds New Report

Report forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016 - 2020.

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.

Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography:

• Americas
• APAC
• EMEA

Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, products in the late pipeline stages will likely be launched during the forecast period. Some of these products include glembatumumab vedotin by Seattle Genetics, trastuzumab by Synthon Biopharmaceuticals, and SGN-35 by Takeda Pharmaceuticals. Some molecules are in the Phase I/II, preclinical, and discovery stages. ADCETRIS is currently under clinical trials for additional indications such as frontline mature T-cell lymphomas, B-cell lymphomas, and CD30-expressing conditions.

Further, the report states that the high developmental costs of antibody conjugates negatively impact the growth of the market.

Key players in the Global Antibody Drug Conjugates Market: F. Hoffmann-La Roche AG, Seattle Genetics Inc., and Takeda Pharmaceutical Company.

Other Prominent Vendors in the market are: AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, and Zymeworks.

Market driver

• Robust late-stage pipeline
• For a full, detailed list, view our report

Market challenge

• High developmental costs
• For a full, detailed list, view our report

Market trend

• Strategic alliances
• For a full, detailed list, view our report

Key questions answered in this report

• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Spanning over 75 pages “Global Antibody Conjugates Drugs Market 2016 - 2020” report covers Executive summary, Scope of the report, Market research methodology, Introduction, Overview of ADCs, Pipeline portfolio, Market landscape, Market segmentation by MOA, Market segmentation by technologies used in ADCs, Geographical segmentation, Market drivers, Impact of drivers, Market challenges, Impact of drivers and challenges, Market trends, Vendor landscape, Appendix.

For more information Visit at: http://mrr.cm/Jqq

Find all Biotechnology report at: http://www.marketresearchreports.com/biotechnology